Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,526 public trials 2,840 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Completed

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

NCT01592370

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +18 more
Locations
  • Local Institution - 0035 Clovis, California, United States
  • Division Of Hematology & Oncology Ctr. For Health Sciences Los Angeles, California, United States
  • Local Institution - 0012 Los Angeles, California, United States
  • Local Institution - 0017 Aurora, Colorado, United States
View all 43 locations
View Trial Details
Completed

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

NCT04266795

Conditions
Acute Myeloid Leukemia (AML), Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • UC Irvine Medical Center Orange, California, United States
  • University of Miami Miller School of Medicine Miami, Florida, United States
View all 57 locations
View Trial Details
Completed

A Study of Colesevelam for Lenalidomide-Associated Diarrhea

NCT03767257

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Diarrhea, +16 more
Locations
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (All Protocol Activities) Commack, New York, United States
View Trial Details
Completed

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

NCT02252172

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Birmingham, Alabama, United States
  • Mobile, Alabama, United States
  • Glendale, Arizona, United States
  • Berkeley, California, United States
View all 206 locations
View Trial Details
Completed

A Study in Adults With Untreated Acute Lymphoblastic Leukemia

NCT00136435

Conditions
Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • University Of Columbia Medical Center New York, United States
  • Manitoba Blood & Marrow Transplant Program CancerCare Manitoba Winnipeg, Manitoba, Canada
View Trial Details
Completed

BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

NCT01711632

Conditions
Hairy Cell Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Scripps Clinic La Jolla, California, United States
  • Northwestern University Evanston, Illinois, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Completed

Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

NCT02680795

Conditions
Hematologic Diseases, Hematologic Neoplasms, Hematological Malignancies, +4 more
Locations
  • John Wayne Cancer Institute @ Providence Saint John's Health Center Santa Monica, California, United States
  • The Oncology Institute of Hope and Innovation Whittier, California, United States
  • Gabrail Cancer Center Research Canton, Ohio, United States
View Trial Details
Completed

Epigenetic Reprogramming in Relapse/Refractory AML

NCT03263936

Conditions
Acute Myelogenous Leukemia, Disease Attributes, Hematologic Diseases, +9 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital Orange County Orange, California, United States
  • UCSF School of Medicine San Francisco, California, United States
  • The Children's Hospital, University of Colorado Aurora, Colorado, United States
View all 33 locations
View Trial Details

Related conditions